European equities traded in the US as American depositary receipts were trending slightly lower late Monday morning, declining 0.16% to 1,278.01 on the S&P Europe Select ADR Index. From continental ...

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $42.02.Don't Miss Our ...

4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

Centiva Capital LP lowered its stake in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) by 37.4% in the third quarter ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Verona Pharma (VRNA – Research Report). The company’s ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

Verona Pharma plc's (NASDAQ:VRNA) Chief Financial Officer, Mark Hahn, recently sold a significant portion of his holdings in the company. The sale comes as the stock trades near its 52-week high ...